Nohla Therapeutics, a Seattle-based biotech corporation announced Tuesday that it has raised $43. 5 mil in a Series A funding round.
The particular round was led by ARCH Venture Partners, a brand new investor in Nohla. Others who participated were 5AM Ventures and the Jagen Group. The company is developing general donor cellular therapies for patients with blood problems and cancers.
The money will help to advance Nohla’ s two lead programs (NLA-101 and NLA-102) which were created from the company’ s platform that has its root base in the Fred Hutchinson Cancer Research Center. The technologies was spun out from the Hutch in September 2015 plus Nohla launched in December. With the latest funding circular, the company has raised a total of $64. 6 mil since its inception.
The goal of the company would be to develop lifesaving transplantation techniques that use cord blood which could potentially make stem cell treatments available to myriad individuals who are unable to find tissue-matched bone marrow donors.
“ The closing of this round is an important landmark for the company as we transition to the next stage of development. The funding provides sufficient capital to advance our 2 lead programs through randomized, controlled clinical trials, underneath the direction of Nohla founder and Chief Medical Official, Dr . Colleen Delaney, ” said Michael Sistenich, temporary Chief Executive Officer of Nohla Therapeutics, in a news release.
Through several clinical studies, more than 100 patients are actually treated with the company’ s universal donor cellular remedies that do not require HLA matching. HLA matching or even human leukocyte antigen (HLA) typing is used to match a patient with a donor for bone marrow or wire blood transplant.
The technology platform created at the Fred Hutchinson Cancer Research Center furthermore claims to be able to promote “ hematopoietic and immune cellular recovery in patients at risk for neutropenia and an infection after intensive chemotherapy and/or radiation treatment for vital diseases, ” the news release noted.
“ The entire team at Arch is excited to lead this particular round of investment in Nohla. We have been impressed along with early clinical results from Dr . Delaney’ s pioneering study and believe that Nohla technology has the potential to help sufferers suffering from a variety of critical diseases, ” said Dr . Steven Gillis, managing director at ARCH in a statement.
Another Seattle company, Universal Cells, is certainly taking a different approach to making stem cells compatible to ensure that tissue/organs are not rejected or do not require matching. This employs gene editing to generate cell lines that do not really express HLA molecules on their cell surfaces. In the event that HLA is not expressed and therefore missing from the cell’ ersus surface, the human immune system is not forced into a response to reject transplanted cells.
Such universal donor tissue have the potential to transform the field of regenerative medication.
Photo: freedigitalphotos user Salvatore Vuono